Distinct signal transduction abnormalities and erythropoietin response in bone marrow hematopoietic cell subpopulations of myelodysplastic syndrome patients. by Spinelli, E et al.
Human Cancer Biology
Distinct Signal Transduction Abnormalities and
Erythropoietin Response in BoneMarrowHematopoietic Cell
Subpopulations of Myelodysplastic Syndrome Patients
Elena Spinelli1, Roberto Caporale2, Francesca Buchi1, Erico Masala1, Antonella Gozzini1, Alessandro Sanna1,
Francesca Sassolini1, Ana Valencia1, Alberto Bosi1, and Valeria Santini1
Abstract
Purpose: Myelodysplastic syndromes (MDS) are heterogeneous clonal diseases characterized by cyto-
penias as a result of ineffective hematopoiesis. Little is known about alterations in signal transduction
pathways in MDS.
Experimental Design:Multiparameter flow cytometry was used to evaluate the proteolytic activation of
caspase-3 and thephosphorylation of extracellular signal-regulated kinase (ERK)1/2, p38mitogen-activated
protein kinase (MAPK), and STAT5 specifically in defined CD34þ, CD45þ, or CD71þCD45 bone marrow
(BM) cells from 60 MDS cases and normal controls, both at baseline and following stimulation with
granulocyte colony-stimulating factor (G-CSF) and erythropoietin.
Results: In CD71þCD45 cells from a subpopulation of 36 MDS cases who were predicted to be
responsive by clinical parameters (endogenous erythropoietin levels, transfusiondependency, percentageof
blasts in theBM), erythropoietin failed to activate ERK1/2or STAT5 in23of 36 cases, but itwas effective in13
of 36 cases, although to a significantly lower degree than inCD71þCD45 cells fromhealthy donor BM. The
erythropoietin response in vivo correlated with in vitro erythropoietin-dependent STAT5 activation in 20 of
22 cases. STAT5was significantly activated at baseline inMDS cells comparedwith normal controls, whereas
caspase-3was activated inCD34þ andCD45þMDScells, andwas activatedmoreoften in theRAandRAEB-1
MDS subtypes. G-CSF stimulation activated ERK1/2 and STAT5 equally in MDS and normal CD34þ cells.
Conclusions:Abnormalities in the response to growth factors are restricted to erythropoietin stimulation
in CD71þCD45 cells and correlate with the clinical response to erythropoietin. Activation of baseline
signal transduction for proliferative and apoptotic signals is altered in MDS but with different patterns
among the various BM subpopulations. Clin Cancer Res; 18(11); 3079–89. 2012 AACR.
Introduction
Myelodysplastic syndromes (MDS) are a group of hema-
tologic neoplastic diseases heterogeneous for clinical pre-
sentation and genetic alterations. The characterization of
biologic properties of myelodysplastic cells in vitro is ham-
pered by lack of animal models and by difficulties in
isolating the cell populations responsible for the disease
and/or its maintenance. Although high throughput techni-
ques have recently identified many genetic lesions present
in MDS, the majority of cases lack an easily detectable
molecular or phenotypic marker. The burden of disease is
routinely evaluated morphologically, by manually scoring
dysplastic cells, and only recently have other methods been
proposed, including flow cytometric analysis (1, 2) or
molecular quantitation of oncogenes such as WT-1
(3, 4). In fact, at present, 3 diagnostic and prognostic
evaluation systems are used to classify MDS, the French-
American-British (FAB) classification (5), the International
Prognostic Score System(IPSS; ref. 6), and theWorldHealth
Organization (WHO) classification (7), along with the
WHO classification–based prognostic scoring system,
WPSS (8). Both prognostic systems are dependent on the
morphologic detection of immature cells and on the pres-
ence of cytogenetic abnormalities.
Cells from the bone marrow (BM) of patients with MDS
have altered signal transduction pathways. In particular, the
erythropoietin receptor is expressed at a normal density on
MDS cells, but STAT5 activation in response to erythropoi-
etin stimulation is defective (9). This observation was
attributed to intracellular structural defects in the erythro-
poietin receptors of MDS cells, but this was not specifically
showed (10, 11). Few studies have been conducted
Authors' Affiliations: 1FU Hematology and 2Department of Laboratory
Medicine, Azienda Ospedaliero Universitaria (AOU) Careggi, University of
Florence, Florence, Italy
Note: Supplementary data for this article are available at Clinical Cancer
Research Online (http://clincancerres.aacrjournals.org/).
Corresponding Author: Valeria Santini, Functional Unit of Hemato-
logy, AOU Careggi, University of Florence, Largo Brambilla 3, Flor-
ence 50134, Italy. Phone: 00390557947296; Fax: 390557947343;
E-mail: santini@unifi.it
doi: 10.1158/1078-0432.CCR-11-0686





on December 22, 2020. © 2012 American Association for Cancer Research.clincancerres.aacrjournals.org Downloaded from 
Published OnlineFirst April 11, 2012; DOI: 10.1158/1078-0432.CCR-11-0686 
regarding the basal activation of proliferative signaling in
MDS marrow progenitors (9, 12). Recently, altered p38
mitogen-activated protein kinase (MAPK) activation has
been showed in MDS (13). Moreover, little information is
available to explain the progressive displacement of normal
hematopoiesis by the MDS clone, for which the nature of
the survival advantage has not been showed (14).
On the other hand, one of the typical clinical manifesta-
tions of MDS, peripheral cytopenia with hyperproliferative
BM and ineffective hemopoiesis, is caused by excessive
premature apoptosis of hematopoietic precursors (15).
In this study, the signal transduction pathways control-
ling proliferation and apoptosis in distinct subpopulations
of MDS BM cells were evaluated to identify a possible
dysplastic signature. Differences in the basal activation of
signaling pathways were evaluated among marrow cell
subtypes and among MDS morphologic subtypes, defined
according to the WHO classification. Signal transduction
was also evaluated in response to erythropoietic- and gran-
ulopoietic-stimulating agents, broadly used in clinics for the
treatment of low-risk IPSS patients with MDS. In particular,
STAT5 phosphorylation in response to erythropoietin was
examined with respect to clinical outcome in theMDS cases
who were treated with erythropoietin based on clinical
parameters (IPSS low/int-1; endogenous erythropoietin <
500 U/L; no transfusion need), which indicated them as




BM blood samples were obtained from 60 patients diag-
nosed with MDS at the Hematology Unit, AOU Careggi,
University of Florence, Florence, Italy. Patient characteris-
tics are reported in Table 1. BM cells from 6 healthy donors
were included in the study. Informed consent was obtained
according to institutional guidelines. MDS diagnosis was
made in accordance with the WHO criteria. Three CMML-1
and 2 CMML-2 cases were diagnosed according to the
morphologic and cytochemical criteria of the FAB classifi-
cation and were included in the study. All analyses were
conducted at the time of diagnosis. BM cells were cultured
and processed, and conventional cytogenetic analysis was
conducted on unstimulated BM cultures after 24 hours by
Trypsin-Giemsa banding (GTG-banding). Karyotypes were
described according to the International System for Human
Cytogenetic Nomenclature (16).
Endogenous erythropoietin serum levels were routinely
evaluated at diagnosis with a chemiluminescent immuno-
metric assay (Immulite 2000 EPO; Siemens Healthcare
Diagnostics Inc.).
Isolation of mononuclear cells from BM samples, cells,
and culture conditions
For in vitro experiments, bonemarrowmononuclear cells
(BMMC) were purified by standard density gradient centri-
fugation (Lympholyte-H; Cedarlane Laboratories Ltd.) and
were maintained in RPMI-1640 supplemented with 10%
Translational Relevance
This study provides one immediate translational
application and two possible clinical developments. The
accuracy and rapidity of the tests described in this report
are therefore ofmajor interest. First, this study provides a
possible means of improving the assessment and pre-
diction of clinical sensitivity to erythropoietin using a
rapid and relatively simple cytofluorimetric assay in
patients with MDS already indicated as possibly respon-
sive on the basis of recognized predictive biologic/clin-
ical parameters. Moreover, from our experimental evi-
dence, granulocyte colony-stimulating factor (G-CSF)
stimulates CD34þ MDS cells at the same rate as normal
progenitors. These data further support the safety of the
use of G-CSF in MDS cases with severe neutropenia.
Finally, these findings show a means of determining the
rate of apoptosis of MDS cells by evaluation of p38
phosphorylation and caspase-3 cleavage. These determi-
nations could be indicative of the efficacy of antiapop-
totic therapy in hypoplastic, low-risk MDS cases.










No. of patients 31 17 10 2
Median age 73 75 68.5 66.5
Gender, M/F 16/15 12/5 7/3 2/0
WHO
RA; RARS 20; 1 7; 1 0; 0 0; 0
RCMD; 5q- 6; 1 6; 0 0; 0 0; 0
RAEB-1; RAEB-2 0; 0 2; 0 5; 4 0; 1
MDS/MPN 1 0 0 0
FAB
CMML-1; CMML-2 2; 0 1; 0 0; 1 0; 1
Karyotype
Normal 30 13 4 0
7q-; 5q- 0 0 1 0
5q- 1 0 0 0
11q- 0 0 1 0
t(9;21) 0 0 0 1
þ8 0 3 1 0
Complex 0 1 3 1
Abbreviations: CMML-1, chronic myelomonocytic leukemia-
1; CMML-2, chronicmyelomonocytic leukemia-2;MDS/MPN,
myelodysplastic/myeloprioliferative neoplasms; RA, refracto-
ry anemia; RARS, RA with ringed sideroblasts; RAEB-1, RA
with excess blasts-1; RAEB-2, RA with excess blasts-2;
RCMD, refractory cytopenia with multilineage dysplasia.
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FBS, glutamine and penicillin/streptomycin at 37C in a
humidified atmosphere containing 5% CO2. Kasumi-1
cells, an AML1/ETO-positive cell line derived from ahuman
acute myelogenous leukemia (AML; ref. 17), was also cul-
tured with the same method.
Stimulation of BMMCs
Kasumi-1 cells and BMMCs from patients with MDS and
healthy donors were resuspended in RPMI-1640 medium
supplemented with 5% FBS. Cells were stimulated with
human recombinant granulocyte colony-stimulating
factor (G-CSF; 100 ng/mL for 10 minutes), erythropoietin
(100 U/mL for 15minutes) or 12-O-tetradecanoylphorbol-
13-acetate (TPA; 400 nmol/L for 10 minutes) at 37C (all
from Sigma-Aldrich). Stimulations were chosen based on
time courses analyses (data not shown).
Cell lysis and immunoblotting
Cells werewashed oncewith ice-cold PBS and solubilized
by incubating for 10 minutes at 95C in Laemmli buffer
(62.5mmol/L Tris/HCl, pH 6.8, 10% glycerol, 0.005%blue
bromophenol, and 2% SDS). Lysates were clarified by
centrifugation (20,000  g, 10 minutes, room tempera-
ture). The protein concentration of the supernatants was
determined by the bicinchoninic acid (BCA) assay (Pierce
Chemical) and 30 mg aliquots of each sample were boiled
for 10 minutes in the presence of 100 mmol/L of 2-mer-
captoethanol. Proteins were separated by SDS-PAGE in a
9% to 15% PAGE and transferred onto polyvinylidene
difluoride membranes (Amersham Biosciences) by electro-
blotting. Membranes were blocked in PBS containing 0.1%
Tween 20 and 1% bovine serum albumin (BSA; T-PBS/1%
BSA; 3hours, room temperature) and incubated in the same
buffer with a rabbit anti-phospho-ERK1/2 primary anti-
body (1:1,000; Cell Signaling Technology; 6–18 hours at
4C).
A horseradish peroxidase (HR)-conjugated secondary
antibody (Sigma-Aldrich) was added for an additional
hour. Antibody-coated protein bands were visualized by
enhanced chemiluminescence detection (Amersham Bios-
ciences). To confirm equal loading of samples, membranes
were incubated in stripping buffer (62.5 mmol/L Tris-HCl,
pH 6.7, 2% SDS, 100 mmol/L 2-mercaptoethanol; 30
minutes, 50C), extensively washed with T-PBS, and
reprobed with a rabbit anti-p38 antibody (1:1,000; Cell
Signaling Technology).
Intracellular phospho-specific flow cytometry
Cells were fixed in BD Cytofix Buffer and permeabilized
with BD Perm Buffer III (both from BD Biosciences)
according to the manufacturer’s instructions and were
treated as described elsewhere (18). BMMCs were incu-
bated with the following monoclonal antibodies directed
to surface proteins: allophycocyanin (APC)-conjugated
CD34 (clone 581), phycoerythrin (PE)-conjugated CD71
(clone M-A712), and peridinin-chlorophyll (PerCP)-con-
jugated CD45 (clone 2D1; all from BD Biosciences). At
the same time, cells were incubated with an Alexa Fluor
488–conjugated IgG1 isotype control (clone MOPC-21)
or with Alexa Fluor 488–conjugated specific antibodies
directed to the following intracellular proteins: phospho-
STAT5 (clone 47), phospho-ERK1/2 (clone 20a), or phos-
pho-p38 MAPK (clone 36/p38; all from BD Biosciences)
or polyclonal cleaved caspase-3 (Cell Signaling Labora-
tories). For analysis, approximately 20,000 events were
collected for each sample using a FACSCanto analyzer
(BD Biosciences) and data were processed with the BD
FacsDiva software.
Statistical and cluster analysis
Differences in basal phosphorylation were compared by
calculating the specificmean fluorescence intensity (MFI) as
the ratio of the MFI for each sample divided by the MFI of
the isotype control.
The MFI cutoff value to consider activated phosphoryla-
tion (>1.2) was established by calculating the MFI median
values  SD of unstimulated normal controls.
A protein was considered strongly activated when the
specificMFIwas greater than 5.0, activatedwhen the specific
MFI was between 2.0 and 5.0, weakly activated when the
specific MFI was between 1.2 and 2.0, and not activated
when the specific MFI was less or equal to 1.2. Changes in
the phosphorylation status of proteins following cytokine
stimulationwere determined by calculating the ratios of the
specific MFIs of stimulated versus unstimulated cell
populations.
The nonparametric Wilcoxon Kruskal–Wallis tests were
used to evaluate statistical significance. P  0.05 was con-
sidered statistically significant. The response to erythropoi-
etin treatment in vivo was evaluated according to IWG
criteria as an increase of 2 g/dL in hemoglobin (Hb) levels
after 8 weeks of erythropoietin treatment or transfusion
independence for more than 8 weeks (19). The correlation
between erythropoietin responses in vivo and in vitro was
calculated by the nonparametric Spearman test. Analyses
were conducted with the StataCorp2003 software program.
To assess the validity of the in vitro results with respect to in
vivo response to erythropoietin, we estimated the sensitivity,
the specificity, and the positive and negative predictive
values with their 95% confidence intervals (CI). Analyses
of flow cytometric data were conducted using unsupervised
algorithms that allow for samples with similar patterns of
protein basal activation or similar cytokine responses in
vitro to be grouped together. Heat maps and dendrograms
were drawn with the open-source versions of the Cluster
and TreeView programs (http://bonsai.ims.u-tokyo.ac.jp/
~mdehoon/software/cluster/software.htm).
Results
Spontaneous basal activation of ERK1/2, STAT5, p38
MAPK, and caspase-3 in CD34þ cells
Basal activation of extracellular signal-regulated kinase
(ERK)1/2, STAT5, p38 MAPK, and caspase-3 in CD34þ
BMMCs was evaluated in 60 patients with MDS and 6
healthy donors. CD34þ cells were not detected in 6 MDS
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cases, leaving 54 evaluable samples (Supplementary Table
S1). The pattern of activation is listed in Table 2.
STAT5 was phosphorylated in the majority of MDS cases
but particularly in 5 of 54 cases (1 RA, 1 RCMD, 2 RAEB-1,
and 1 RAEB-2). Caspase-3was also strongly activated in 5 of
54 cases (1 RA, 1 RARS, 1 RCMD, 1 RAEB-1, and 1 RAEB-2).
Healthydonor cells didnot exhibit basal activationof anyof
the proteins studied (Supplementary Fig. S1).
Statistical analysis showed that STAT5 and caspase-3were
significantly activated in CD34þ MDS cells compared
with normal donor cells (P ¼ 0.001 and P ¼ 0.002,
respectively; Fig. 1A) and that STAT5 was significantly
phosphorylated in the RA and RAEB-1 WHO subgroups as
compared with healthy donors (P < 0.001 and P < 0.001).
A heterogeneous pattern of basal activation was observed
by cluster analysis, in that MDS cases belonging to the same
WHO classification subtype did not cluster together (Fig.
1B). Flow cytometric analysis of ERK1/2, STAT5, p38MAPK,
and caspase-3 basal activation in one representative case
(#18) is shown in Supplementary Fig. S2.
Spontaneous basal activation of ERK1/2, STAT5, p38
MAPK, and caspase-3 in CD45þ cells
Basal activation of ERK1/2, p38 MAPK, STAT5, and
caspase-3 was studied in CD45þ cells obtained from 45 of
60 patients with MDS and 6 healthy donors (Supplemen-
tary Table S2). The pattern of activation is depicted
in Table 2.
ERK1/2 and p38MAPK phosphorylation was a rare event
in these cells. The intensity of phosphorylation of STAT5
and caspase-3 was heterogenous butweak in themajority of
cases (1.2 <MFI < 2). BM cells from the normal donors did
not show any basal activation of the studied proteins
(Supplementary Fig. S3).
Statistical analysis showed that STAT5 and caspase-3were
significantly activated in CD45þ MDS cells compared with
healthy donors controls (P < 0.001 and P ¼ 0.003,
respectively; Fig. 1C) and that STAT5 was significantly
phosphorylated in patients with the RA and RAEB-1 sub-
types (P<0.001 andP¼ 0.001, respectively) comparedwith
normal cases.
Cluster analysis showed a heterogenous pattern of
activation, and the cases belonging to the same WHO
subtypes did not cluster together, although normal cases
did (Fig. 1D).
Spontaneous basal activation of ERK1/2, STAT5, p38
MAPK, and caspase-3 in CD71þCD45 cells
Basal activation of ERK1/2, STAT5, p38 MAPK, and
caspase-3 was studied in BM from 45 of 60 patients with
MDS and 6 normal donors. Two of the MDS cases analyzed
did not contain CD71þCD45 cells. The activation of
signaling pathways in this subpopulation was low overall
and is shown in Table 2.
Healthy donor cells and MDS cases did not present
basal activation of ERK1/2, p38 MAPK, or caspase-3
(Supplementary Fig. S4). STAT5 was the only protein
significantly activated in the CD71þCD45 subpopula-
tion compared with normal cells (P ¼ 0.006; Fig. 1E).
Cases of RA and RAEB-1 (P ¼ 0.001 and P ¼ 0.001,
respectively) showed the highest levels of STAT5 activa-
tion in absence of any stimuli. Five RA cases with the
highest STAT5 activation (MFI > 3) also grouped together
by cluster analysis (Fig. 1F).
Cytokine response in vitro
Activation of signaling proteins in Kasumi-1 and healthy
control cells. To validate themethod, Kasumi-1 cells (85%
CD34þ) were stimulated with TPA, a known activator of
ERK1/2. Strong activation of ERK1/2 was observed by flow
cytometry after TPA treatment. This result was qualitatively
validated by immunolotting (Fig. 2A and B).
In parallel, ERK1/2 and STAT5 activation was also
studied in normal BMMCs after erythropoietin treatment
for 5, 15, 30, and 60 minutes or TPA treatment for 10
minutes.
After 15 minutes of erythropoietin treatment,
CD71þCD45 cells showed no ERK1/2 activation (Fig.
2C, bottom left), and STAT5 phosphorylation peaked at
this time (data not shown). The activation of ERK1/2 was
not visible by immunoblotting of total BMMCs, which
contains only 17.6% CD71þCD45 cells (Fig. 2D).
Moreover, ERK1/2 activation following TPA stimulation
was observed inCD45þ cells (79%of the total BMMCs) and
in CD34þ cells (1.4% of the total BMMCs) but not in
CD71þCD45 cells (Fig. 2C, bottom right). This result was
qualitatively validated by immunoblotting analysis of total
BMMCs (Fig. 2D).
Erythropoietin stimulation. The response to erythropoi-
etin stimulation was examined in 38 of 60MDS cases and 6
healthy donors. TwoMDScases hadnoCD71þCD45 cells.
Erythropoietin did not modify the activation of ERK1/2,
p38 MAPK, or caspase-3 in CD34þ, CD45þ, or
CD71þCD45 MDS cells or the activation of STAT5 in
CD34þ or CD45þ MDS cells. However, in CD71þCD45
cells, STAT5 phosphorylation was induced at a ratio of MFI
1.3- to 2.5-fold by erythropoietin in 13 of 36 patients with
MDS belonging to various WHO subtypes and 2.1- to 2.9-
fold in all healthy donors. The remainingMDS cases did not
Table 2. Pattern of spontaneous pathway





CD34þ cells 7/54 45/54 11/54 43/54
CD45þ cells 3/45 34/45 6/45 34/45
CD71þCD45
cells
1/43 28/43 4/43 12/43
NOTE: The ratio of MDS cases considered positive for
spontaneous activation are reportedwith respect to the total
number of cases analyzed.
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showphosphorylation of STAT5 after in vitro treatmentwith
erythropoietin (Supplementary Table S5). Flow cytometric
analysis of STAT5 activation after erythropoietin stimula-
tion in one representative case (#34) is shown in Supple-
mentary Fig. S5A.
Statistical analysis indicated that STAT5 phosphorylation
after erythropoietin stimulation was significantly lower in
CD71þCD45 MDS cells than in CD71þCD45 cells from
healthy donors (P < 0.001; Fig. 3A).
It is interesting to note that none of the MDS cases
responsive to erythropoietin in vitro showedbasal activation
of caspase-3 inCD71þCD45 cells, and conversely, none of
the MDS cases with caspase-3 basal activation responded to
erythropoietin.
Three main groupings were visible upon cluster analysis.
Cluster 1 included the 6 healthy donors, one RCMD case
and one CMML-2 case. Cluster 2 contained 11 MDS
responding to erythropoietin and belonging to various
WHO subtypes; STAT5 activation in these cases was lower
than in healthy donors. Cluster 3 included MDS cases not
responding to erythropoietin (Fig. 3B). Subsequently, the
in vivo response to erythropoietin was evaluated in 22
nontransfused patients with MDS. These patients were
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Figure 1. A, ERK1/2, STAT5, p38MAPK, and caspase-3 basal activation inCD34þBMMCs frompatientswithMDS (n¼54) and normal (NORM) controls (n¼6)
is indicated as theMFI of the sample divided by theMFI of the isotype control (,P < 0.01). B, unsupervised hierarchical clustering of cytofluorimetric data for
basal activation of CD34þ 54 MDS cases and 6 normal BMMC controls. Hierarchical clustering of MDS samples analyzed for the activation of 4
intracellular proteins and 3 surface markers. The hierarchical clustering algorithm is based on the complete linkage method and uses Euclidean distances as
measures of similar/dissimilar behavior. The heat map depicts the activation level values for each of individual sample; columns represent MDS samples and
rows represent the proteins analyzed. The activation level from 0% (black) to 100% (intense red; pixel setting 5) was calculated as the MFI of staining
with the specific antibody divided by the MFI of the isotype control. The MDS cases are labeled by their progressive patient number. C, ERK1/2, STAT5, p38
MAPK, and caspase-3 basal activation in CD45þMDScells (n¼ 45) and normal BMMCs (n¼ 6) is indicated as in (A). D, unsupervised hierarchical clustering of
cytofluorimetric data about basal activation of CD45þ cells from 45 MDS cases and 6 normal BMMC samples. For details, see (B). E, basal activation
of ERK1/2,STAT5,p38MAPK, andcaspase-3 inCD71þCD45MDScells (n¼45) andnormalBMMCs (n¼6) is indicatedas in (A). F, unsupervisedhierarchical
clustering of cytofluorimetric data about basal activation of CD71þCD45 MDS cells from 43 MDS cases and 6 normal controls. For details, see (B).
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erythropoietin according to accepted clinical criteria, in that
all 22 were transfusion-independent, with endogenous
serum erythropoietin levels <500 U/L, and 17 of 22 had
an absence of blasts in the BM. Clinical response to eryth-
ropoietin was defined according to IGW 2006 criteria (19)
as an increase of 2 g/dL in Hb levels after 8 weeks of
erythropoietin treatment. Erythropoietin response in vitro
was defined as a greater than 1.2-foldMFI increase in STAT5
activation. Characteristics of patients treated with erythro-
poietin are reported in Fig. 3C. A strong correlation between
the erythropoietin response in vitro and in the clinic was
observed in 20 of 22 cases (90.9%; the Spearman r ¼ 0.62
and P¼ 0.002; Fig. 3D and Supplementary Table S6). The in
vitro response was highly predictive of in vivo response to
erythropoietin, with a sensitivity of 71% (95% CI, 36.0–
92.0), a specificity of 100% (95% CI, 80.0–100.0), a pos-
itive predictive value of 100% (95% CI, 56.6–100.0), and a
negative predictive value of 88% (95% CI, 66.0–96.7).
The 2 MDS cases that did not show a correlation with
erythropoietin response in vivo had high basal STAT5
phosphorylation (2  MFI < 5). Moreover, in 8 of 22
cases the immunophenotype of CD34þ cells was evalu-
ated with a panel of antibodies applied by Westers and
colleagues (20). Consistent with these authors’ observa-
tions, in 5 of 8 MDS cases the aberrant immunopheno-
type of myeloid blasts correlated with erythropoietin
treatment failure, whereas 1 of 8 case did respond to
erythropoietin and presented a normal CD34þ pheno-
type. In contrast, the remaining 2 of 8 cases responded to
erythropoietin treatment in vivo, despite an aberrant
CD34þ phenotypic pattern.
G-CSF stimulation. G-CSF stimulation was examined
in 40 of 60 MDS cases and 6 healthy donors. This analysis
could not be conducted in 6 MDS cases in which CD34þ
cells were absent. G-CSF did not modify the activation of
p38 MAPK or caspase-3 in any cellular subpopulations.
G-CSF stimulation had no effect on ERK1/2 or STAT5
phosphorylation in CD71þCD45 MDS cells, whereas it
induced STAT5 activation in CD45þ cells in 9 of 40 cases
(data not shown). CD34þ cells showed a 1.3- to 10-fold
G-CSF–dependent activation of STAT5 in 32 of 34 MDS
cases, whereas in normal cells, STAT5 was activated 1.9- to
2.8-fold in response to G-CSF (Supplementary Table S4).
Statistical analysis indicated no significant difference
in STAT5 activation in response to G-CSF in CD34þ
cells from MDS cases as compared with normal controls
(P ¼ 0.49; Fig. 4A). Cluster analysis revealed that the
pattern of STAT5 phosphorylation after G-CSF was het-
erogeneous (Fig. 4B). Flow cytometric analysis of STAT5
activation after G-CSF stimulation in one case (#37) is
represented in Supplementary Fig. S5B. Moreover, CD34þ
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Figure 2. ERK1/2 activation in
Kasumi-1 cells and normal
BMMCs. A, flow cytometric
analysis of ERK1/2 activation
before (top right) and after (bottom
right) TPA treatment in Kasumi-1
cells. B, immunoblot analysis of
ERK1/2 activation before and after
TPA treatment in Kasumi-1 cells.
Full-length blots are presented in
Supplementary Fig. S6A. C, flow
cytometric analysis of ERK1/2
activation before and after
erythropoietin (EPO) and TPA
treatment inBMMCsobtained from
healthy donors: isotypic control
(top left), p-ERK1/2 basal
activation (top right), p-ERK1/2
activation after erythropoietin
treatment (top left), and p-ERK1/2
activation after TPA treatment
(bottom right). The CD45þ cells are
indicated in orange, the
CD71þCD45 cells are in violet, the
CD34þ cells are shown in dark
blue, and all activated cells are
shown in light blue. D, immunoblot
analysis of ERK1/2 activation
before and after TPA and
erythropoietin treatment of normal
BMMCs. Full-length blots are
presented in Supplementary Fig.
S6B.
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of 8 MDS cases and in all normal cases with an MFI ratio
of between 1.3 and 1.9 (Fig. 4C).
Discussion
MDS are a complex group of diseases. Very few studies
have focused on dissecting the signaling pathways in MDS
cells (13, 21). This study evaluated the spontaneous basal
activation of ERK1/2, p38 MAPK, STAT5, and caspase-3 in
60 primary human MDS cases, and the modulation of this
activation by erythropoietin and G-CSF using a flow cyto-
metric method which allowed quantitation of phosphory-
lation in the distinct CD45þ, CD34þ, and CD71þCD45
BMMC subpopulations
The spontaneous activation of ERK1/2, p38 MAPK,
STAT5, and caspase-3 differed markedly between normal
and MDS cells and was highly heterogeneous among MDS
cases and also among the different MDS cell subpopula-
tions studied. This is due to the fact that, in MDS marrow,
progenitors with different stages of differentiation and
different genotypes are present. Our aim was not to study
a selected subpopulation, as done in gene expression pro-
filing studies, but to examine the difference in pathways
among these subpopulations.
The intensity of activation of STAT5, caspase-3, and
p38, and the number of cases in which activation was
observed, was highest in CD34þ cells, suggesting that
this is the most "active" subpopulation in MDS. This
enhanced signaling could contribute to the progressive
depletion of early hematopoietic cells seen in patients
with MDS due to defective self-renewal, differentiation,
and quiescence (22).
ERK1/2 is only marginally activated in basal conditions
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Figure 3. A, STAT5 activation by erythropoietin (EPO) inCD71þCD45 cells. erythropoietin-dependent activation of STAT5 inCD71þCD45MDScells (n¼ 36)
and healthy donor cells (n¼ 6) is indicated as the ratio of theMFI from stimulated to unstimulated cells (,P < 0.01). B, unsupervised hierarchical clustering of
cytofluorimetric data about STAT5 phosphorylation in CD71þCD45 cells from 36 MDS cases and 6 normal BMMC samples after erythropoietin
stimulation. The hierarchical clustering algorithm is based on the complete linkage method and uses Euclidean distances as measures of similar/dissimilar
behavior. The heat map depicts the activation level values for each of the individual sample. Columns represent MDS samples. Activation levels from 0%
(black) to 100% (intense red; pixel setting 3) were calculated as the ratio of the STAT5-specific MFI in stimulated versus unstimulated CD71þCD45
cells. C, characteristics of patients with MDS treated with erythropoietin. D, correlation between erythropoietin response in vitro and in vivo. The x-axis
indicates STAT5 activation following erythropoietin stimulation whereas the y-axis indicates the increase in hemoglobin levels after erythropoietin
treatment in vivo. The cases with positive or negative responses to erythropoietin fall within quadrant I (n¼ 5) and III (n¼ 15), respectively (positive correlation
between in vitro and in vivo responses). The cases with a contrasting response to erythropoietin (negative correlation between in vitro and in vivo responses)
fall within in quadrant II (n ¼ 2) and IV (n ¼ 0). The original graphic is presented in Supplementary Fig. S6C.
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CD71þCD45 cells, both in normal donors and in MDS
cases. The erythroid subpopulation appeared inert in
normal BMMCs, whereas CD71þCD45 cells from myelo-
dysplastic BMs showed basal phosphorylation of STAT5 in
approximately half of the cases studied, which can be
interpreted as a sign of ineffective erythropoiesis. There is
a lack of correlation between the phosphorylation pattern
and the WHO (or FAB) classification, reflecting possibly
inadequacy of currentMDSclassification systems,which are
based only on morphologic features.
While few data for activated proliferative pathways are
available, literature mainly concerns gene silencing or over-
expression/mutation of oncogenes correlated with progres-
sion of MDS to AML (23–26).
In addition, STAT5 and ERK1/2 activation in response
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Figure 4. A, STAT5 activation by
G-CSF in CD34þ cells. G-CSF–
dependent activation of STAT5 in
CD34þ MDS cells (n ¼ 34) and
healthy donor cells (n ¼ 6) is
calculated as the ratio of the MFI of
stimulated cells to unstimulated
cells. B, unsupervised hierarchical
clustering of cytofluorimetric data
of STAT5 phosphorylation in
CD34þ cells from 34 MDS cases
and 6 normal BMMC samples after
G-CSF stimulation. The
hierarchical clustering algorithm is
based on the complete linkage
method and uses Euclidean
distances as measures of similar/
dissimilar behavior. The heat map
depicts the activation level values
for each individual sample.
Columns represent MDS samples.
Activation level from 0% (black) to
100% (intense red; pixel setting 5)
was calculated as the ratio of the
STAT5-specific MFI in stimulated
versus unstimulated CD34þ cells.
C, ERK1/2 activation by G-CSF in
CD34þ cells. G-CSF–dependent
activation of ERK1/2 in CD34þ
MDScells (n¼8) andhealthy donor
cells (n¼ 6) is indicated by the ratio
of the MFI of stimulated versus
unstimulated cells.
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marrow cells. A defect in STAT5 gene expression char-
acterizes lenalidomide responsiveness irrespective of the
presence of the 5q deletion and is an essential prereq-
uisite for lenalidomide sensitivity (27). As already shown
by other authors, STAT5 activation in response to in vitro
erythropoietin was absent or significantly reduced in all
MDS cases compared with normal controls. No signifi-
cant differences in the presence of erythropoietin respon-
sive, nor in the burden of the MDS clone, as indicated by
abnormal metaphases (data not shown), were detected
between responders and nonresponders. This abnormal-
ity seems to allow a clear distinction between normal
and MDS CD71þCD45 progenitors. These data are
consistent with recent reports (21). This intrinsic defect
in erythroid development is characteristic of the disease
and mainly functionally affects CD71þCD45 cells
(9, 27). Even when all metaphases scored are abnormal,
the response to erythropoietin may be present and thus
attributed to the MDS clone (case #25; see Results).
In vitro response to erythropoietin, measured by cyto-
fluorimetry in CD71þCD45 cells, correlated strictly
with the in vivo response. This method could thus be
used as a test that could accurately predict clinically
responsive patients, even among those presenting with
favorable biologic/clinical parameters such as endoge-
nous erythropoietin levels <500 U/L, low marrow blasts,
and tranfusion independency. This analysis particularly
focused on such MDS cases. These characteristics identify
the group of MDS cases with the lowest Nordic score
(28) and who therefore are predicted to have the highest
probability of response to erythropoietin (plus G-CSF)
treatment, as confirmed in a recent meta-analysis (29).
Within this subset of possibly responsive patients, the
cytofluorimetric test described here strongly predicted
the clinically nonresponsive patients. Recently, an aber-
rant phenotype of CD34þ cells in patients with MDS has
been shown to be predictive of the response to erythro-
poietin (20). The MDS cases with an aberrant CD34þ
phenotype according to ELN guidelines (1) were also
erythropoietin insensitive in the STAT5 phosphorylation
test, confirming the correlation between erythropoietin
insensitivity and CD34 immunophenotype. An inconsis-
tency of the 2 types of evaluation was observed only in
one isolated case. Therefore, the test described in this
report has a very high predictive power for the in vivo
erythropoietin response, particularly as it is independent
of the presence of CD34þ cells. A correlation between the
flow score of BM cells and the IPSS score has been shown
in MDS (30). In that study, and in follow-up studies by
the same group, the predictability of the response to
treatments like hematopoietic stem cell transplantation
(HSCT) and immunosuppressive drugs was evaluated
(31, 32).
Attempts have been made to distinguish an erythro-
poietin response signature in MDS and, in fact, differen-
tial expression of 37 genes could separate erythropoietin-
responsive and nonresponsive cases with similar biologic
and clinical characteristics (33). None of the genes dif-
ferentially expressed were directly linked to erythroid
maturation. Similarly to what is observed for erythropoi-
etin, non-5q MDS cases responding to lenalidomide did
not vary significantly from nonresponders with respect to
clinical characteristics such as age, BM cell counts, or
peripheral blood cell counts, but were identified based
only on gene signature (34).
A correlation between activated ERK1/2 in BM cells and
clinical response to erythropoietin has been shown
recently (21). We originally attributed our failure to
observe a high level of phosphorylation of ERK1/2 in
response to erythropoietin to a methodology problem;
however, TPA strongly activated ERK1/2 not only in MDS
cells, but also in an AML cell line and in normal donor
cells. It therefore seems that activation of the ERK1/2
pathway, although present, is not strong or frequent in
MDS cells or normal BMMCs.
Finally, G-CSF promotes STAT5 and ERK1/2 phosphor-
ylation at a level that is comparable with that observed in
normal CD34þ cells. The response to G-CSF is therefore
not altered in CD34þMDS cells, and thus does not identify
a pattern typical of dysplastic hematopoietic stem cells.
Most probably, earlier stem cell populations such as
CD34þCD38 or CD133þ cells should be evaluated in this
sense, as gene expression profiling has indicated significant
differences compared with normal counterparts (35). In
addition, these data could in fact support a safe, and
consequently broader, use of G-CSF in the treatment of
MDS.
This study provides the first evidence that is possible to
identify a dysplastic phosphorylation signature, opening
novel possibilities for investigation of the heterogeneous
pathophysiology of MDS. These data also show that the
erythropoietin clinical response may be predicted with a
rapid cytofluorimetric test that is more accurate than pre-
viously applied biologic/clinical parameters.
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